Ascelia Pharma AB (FRA:7ZA) Total Stockholders Equity : €5.28 Mil (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Ascelia Pharma AB Total Stockholders Equity?

Ascelia Pharma AB's Total Stockholders Equity for the quarter that ended in Mar. 2025 was €5.28 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Ascelia Pharma AB's Book Value per Share for the quarter that ended in Mar. 2025 was €0.05. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Ascelia Pharma AB's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.47.

Ascelia Pharma AB Total Stockholders Equity Historical Data

The historical data trend for Ascelia Pharma AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB Total Stockholders Equity Chart

Ascelia Pharma AB Annual Data

Trend

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

23.20

29.97

16.45

6.65

6.86

Ascelia Pharma AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															5.56	4.22	9.48	6.86	5.28

Ascelia Pharma AB (FRA:7ZA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Ascelia Pharma AB's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(5.278	-	0)	/	96.106
	=	0.05

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Ascelia Pharma AB's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.424	+	0.063)	/	5.278
	=	0.47

Ascelia Pharma AB Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascelia Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (FRA:7ZA) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ACE:Sweden

Address

Hyllie Boulevard 34, Malmo, SWE, 215 32

Website

https://www.ascelia.com

Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.

Ascelia Pharma AB Headlines

No Headlines